Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19
Meaningful new therapeutic options are desperately needed for possibly millions of people around the world who will develop severe or critical COVID-19 disease

Merck, known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19.

“Meaningful new therapeutic options are desperately needed for possibly millions of people around the world who will develop severe or critical COVID-19 disease,” said Dr. Roger M. Perlmutter, President Merck Research Laboratories. “Recent clinical investigations support the view that CD24Fc may provide benefit beyond standard of care therapy for COVID-19 patients requiring oxygen support, and hence will represent an important addition to the Merck pipeline of investigational medicines and vaccines designed to address the COVID-19 pandemic.”

Interim analysis of data from 203 participants (75% of the planned enrollment) reported by OncoImmune indicated that patients with severe or critical COVID-19 treated with a single dose of CD24Fc showed a 60% higher probability of improvement in clinical status, as defined by the protocol, compared to placebo. The risk of death or respiratory failure was reduced by more than 50%. Detailed results will be submitted for publication in a peer-reviewed medical journal.

“Outstanding work by the OncoImmune team has provided compelling evidence regarding the use of CD24Fc in patients with severe and critical COVID-19 in our Phase 3 Trial,” said Yang Liu, PhD, Co-founder and Chief Executive Officer of OncoImmune. “We look forward to working with the scientists and manufacturing engineers at Merck as well as regulators as we seek to accelerate the global development of this potentially important therapy.”

Under the agreement, prior to the completion of the acquisition, OncoImmune will spin-out certain rights and assets unrelated to the CD24Fc program to a new entity to be owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck will invest $50 million, and become a minority shareholder, in the new entity.

The closing of the acquisition, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected before the end of 2020.

OncoImmune was represented by Goodwin Procter LLP as legal advisor and Guggenheim Securities as financial advisor.

Tags : #LatestPharmaNewsNov23 #LatestMerckNewsNov23 #TreatmentforCOVID19 #Coronavirustreatment

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

No health, gender and economic justice without ending wars, invasions and genocidesJuly 19, 2025
Venus Remedies Secures WHO GDP Endorsement for Best-in-Class Pharma LogisticsJuly 18, 2025
Single Surgeon Performs 17 Joint Replacements in 8 Hours at CARE Banjara, Setting New Benchmark in Orthopedic ExcellenceJuly 17, 2025
Sterling Hospitals Rajkot Achieves a Medical Milestone: Successfully Treats Rare and Life-Threatening Heart Condition RSOV Without Open Heart SurgeryJuly 17, 2025
Vidyadhan Alumni and Students Successfully Host Third Annual Blood Donation DriveJuly 17, 2025
HOSMAC Signs MoU with Gulf Medical University as Industry Partner to Strengthen Healthcare Education and CollaborationJuly 17, 2025
Why Teens Can’t Wake Up Early: The Hidden Problem of School TimingsJuly 17, 2025
Code Blue to Code Smart: How AI is Reshaping ICU Risk StratificationJuly 17, 2025
TERN Group Launches Its 7th Training Centre - and First Dedicated to Japanese Language & Careers - in GuwahatiJuly 16, 2025
Sri Sathya Sai Heart Hospital Ahmedabad and Rajkot signed an MOU with Gujarat Health Department for free heart surgery for needy children and adults July 16, 2025
No health without rights, says Shobha Shukla SDG-3 Lead Discussant at UN meetJuly 15, 2025
30 Minutes To Freedom, Robotic Surgery Ends 89-YO’s Swallowing NightmareJuly 15, 2025
Himalaya Wellness Champions Bhringaraja in New Anti-Hair Fall Campaign with a Tale of FriendshipJuly 15, 2025
ViiV Healthcare and Medicines Patent Pool extends voluntary licensing agreement to enable access to long-acting injectable HIV treatment July 15, 2025
Reforming global financial architecture is critical for gender equality and right to healthJuly 14, 2025
Francesco Arezzo takes office as president of Rotary InternationalJuly 14, 2025
CBM India Highlights Inclusive Eye Health at VISION 2020: The Right to Sight – INDIA 19th Annual ConferenceJuly 14, 2025
Crompton Introduces Ameo Fresh Nutri Blender, Reinforcing Its Promise of ‘Healthy Choices Made Easy’July 14, 2025
NMC Notifies Medical Institutions (Qualifications of Faculty) Regulations, 2025 to Expand Medical Education Capacity and Strengthen Faculty Availability July 14, 2025
India’s Roads, India’s Pain: Healing Beyond the HospitalJuly 14, 2025